Skip to main content
BRVE
NASDAQ Life Sciences

Braveheart's HCM Drug Holds Obstruction Gains at 52 Weeks With No Serious Events

Tom Rudovsky · Reported by Wiseek News
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$18.3
Mkt Cap
$1.648B
52W Low
$16.7
52W High
$32
52W Position info
9.6% above low
Off High info
43% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

BRVE is trading near its 52-week low of $16.7 (9.6% above the low).

Summary

Braveheart reported 52-week data from a 42-patient open-label extension of HRS/BHB-1893 in hypertrophic cardiomyopathy: 79% of patients had a Valsalva LVOT gradient below 30 mmHg, peak oxygen uptake rose 2.7 mL/kg/min and KCCQ-CSS symptom scores improved 17.3 points from extension baseline. No on-treatment severe or serious adverse events were reported. The results support durability and tolerability, but the extension is open-label and uncontrolled, so they don't establish efficacy on their own. This follows the September 8-K where the company reported $122.8M in cash ($527.3M pro forma for the IPO) and started the Phase 3 LIONHEART program. The next real test is the planned fixed-dose Phase 2b oHCM study, which would show whether the dose-simplification effect holds in a controlled trial.

At the time of this announcement, BRVE was trading at $18.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $16.70 to $32.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

BRVE - Latest Insights

BRVE
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.39 info
Change: +$0.770 (+4%) info
Market Cap: $1.832B info
BRVE
Nov 10, 2026, 4:03 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.39 info
Change: +$0.770 (+4%) info
Market Cap: $1.832B info
BRVE
Nov 06, 2026, 3:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.39 info
Change: +$2.09 (+11%) info
Market Cap: $1.832B info
BRVE
Sep 08, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.41
Real-time Price: $20.39 info
Change: -$9.02 (-31%) info
Market Cap: $1.832B info
BRVE
Aug 14, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $27.03
Real-time Price: $20.39 info
Change: -$6.64 (-25%) info
Market Cap: $1.832B info